The Insight Labs Daily.

The stakes are concentrated in a few categories. Front-of-pack warning labels in countries like Chile and Mexico hit sugary drinks, instant noodles and packaged snacks hardest, and those categories sit at the centre of Nestle's India portfolio. A star-rating system, which industry has generally preferred over warning symbols, tends to be gentler on reformulated products.

For Indian FMCG at large, the design choice matters more than the deadline. A warning-label regime would reprice shelf appeal overnight for hundreds of brands, while a rating regime rewards whoever reformulates fastest. Companies that started cutting sugar and sodium early would walk into the new rules with an advantage.

The mix matters. Block deals and offers-for-sale move money between investors without funding a single factory, while fresh issues and QIPs put capital onto company balance sheets. A record year built mostly on exits would say more about sellers finding a window than about corporate India investing.

This week alone carried the pattern: GIC sold Rs 1,758 crore of Ather to Hero, Ribbit Capital sold Rs 2,217 crore of Groww, and Lightspeed exited PhysicsWallah in a block. The venture capital that entered India between 2015 and 2021 is leaving through the public market, and FY27 looks like its widest door yet.

A flat year at Zerodha is a reading on the Indian retail investor, because the firm never advertises and grows only when people choose to trade. Flat revenue means the derivatives boom that powered FY24 and FY25 has genuinely paused, and the regulator's clampdown on options did what it was designed to do.

The strategic question is margin. Broking fees compress toward zero everywhere in the world, and the firms that survive convert distribution into lending and asset management. Zerodha moving 10% of revenue into MTF within two years suggests it read that map early. The next number to watch is whether its fund and lending arms can grow faster than its brokerage shrinks.

The sequencing is the strategy. Wellness brands usually launch a product first and add medical credibility later, once regulators or customers demand it. Temple is doing the reverse: assembling clinicians and a functioning practice before revealing what it will sell. That ordering suggests the product will lean on medical claims, which are exactly the claims that need doctors behind them.

It also says something about where the money for longevity sits today. Longevous served paying clients in London, a market where preventive health commands premium pricing. Testing protocols on customers who already pay for them, then bringing the playbook to India, is a cheaper education than learning on a market that has not yet formed.

The unit economics explain the investor interest. Astrology consultations are paid per minute, the expert is a gig supplier rather than an employee, and the customer arrives with high intent. That is closer to a marketplace with 70% take-rate potential than to a content app chasing advertising.

The AI layer is the part worth watching. Sentiment analysis applied to a spiritual consultation blurs the line between service and persuasion, and the category is entirely unregulated. As faith-tech scales into crores of consultations, the question of what these platforms owe emotionally vulnerable users will arrive before any rulebook does.